Luvox

Depressive illness, symptoms of depressive disorder & obsessive compulsive disorder (OCD).

Depression Initially 50 or 100 mg daily as single dose in the evening, increase dose gradually until usual effective dose: 100 mg daily is reached. Prevention of depression recurrence 100 mg daily as single dose. OCD Adult Initially 50 mg daily for 3-4 days, increase dose gradually until usual effective dose: 100-300 mg daily is reached. Max: 300 mg daily. Adolescent & childn from 8 yr Initially 25 mg daily preferably at bedtime, may be increased in 25-mg increments every 4-7 days until usual effective dose: 50-200 mg daily is reached. Max: 200 mg daily.

May be taken with or without food: Swallow whole, do not chew.

Hypersensitivity. Combination w/ tizanidine, MAOIs, pimozide, ramelteon.

Discontinue use if seizures occur or seizure frequency increases; serotonin syndrome or NMS-like events develop. Avoid use in patients w/ unstable epilepsy. Monitor clinical worsening, suicidal behaviour or thoughts & unusual behaviour changes; patients w/ controlled epilepsy. History of suicide-related events & exhibiting significant degree of suicidal ideation; convulsive disorders; bleeding disorders & predisposing conditions eg, thrombocytopenia or coagulation disorders; DM, disturbed glycaemic control; mania/hypomania. Akathisia/psychomotor restlessness; patients w/ risk of QT prolongation; raised IOP or acute narrow-angle glaucoma. May cause sexual dysfunction symptoms. Not to be co-administered w/ terfenadine, astemizole, cisapride. Concomitant use w/ SSRIs, drugs affecting platelet function eg, atypical antipsychotics & phenothiazines, most TCAs, ASA, NSAIDs; drugs increasing risk of bleeding; electroconvulsive therapy. Long-term use. Avoid abrupt w/drawal. May affect ability to drive & use machines. Hepatic or renal insufficiency. May impair fertility. Not to be used in women of childbearing potential, during pregnancy & lactation. Not to be used in childn & adolescents <18 yr w/ depression. Elderly.

Anorexia; agitation, nervousness, anxiety, insomnia, somnolence, tremor, headache, dizziness; palpitations/tachycardia; abdominal pain, constipation, diarrhoea, dry mouth, dyspepsia, nausea, vomiting; hyperhydrosis; asthenia, malaise.

Risk of serotonin syndrome w/ MAOIs. Increased/decreased levels of CYP-metabolised drugs. Increased AUC & C_max of ramelteon. Increased plasma levels of TCAs (eg, clomipramine, imipramine, amitriptyline), neuroleptics (eg, clozapine, olanzapine, quetiapine), benzodiazepines (eg, triazolam, midazolam, alprazolam, diazepam), ropinirol, propranolol, caffeine. Increased plasma conc & prolonged prothrombin time of warfarin. Cardiac toxicity w/ thioridazine. Enhanced serotonergic effects w/ other serotonergic agents eg, triptans, tramadol, buprenorphine, buprenorphine/naloxone, SSRIs, St. John's wort prep; lithium. Increased risk of haemorrhage w/ oral anticoagulants. Avoid use w/ alcohol. Concomitant use of drugs w/ narrow therapeutic index; terfenadine, astemizole, cisapride, sildenafil.

Antidepressants

N06AB08 - fluvoxamine ; Belongs to the class of selective serotonin reuptake inhibitors. Used in the management of depression.

B